

## Engagement Report for Service Specifications

<b>Unique Reference Number</b>	1642
<b>Specification Title</b>	Sarcoma Cancer
<b>Lead Commissioner</b>	Rupi Dev
<b>Clinical Reference Group</b>	Specialised Cancer Surgery Clinical Reference Group (CRG)
Which stakeholders were contacted to be involved in service specification development?	<p>The draft service specification was initially developed by the Sarcoma CRG which is now part of the Specialised Cancer Surgery CRG. The working group responsible for further developing this service specification was conducted in line with the service specification development methodology.</p> <p>The working group included Patient and Public Voice (PPV) representation with Sarcoma UK being involved in the development of the draft service specification.</p>
Identify the relevant Royal College or Professional Society to the specification and indicate how they have been involved	<p>Both the Royal College of Surgeons and the British Association of Surgical Oncology (BASO) are members of the Specialised Cancer Surgery CRG and were invited to comment on the draft service specification.</p> <p>The Royal College of Pathologists and the Society for Cardiothoracic Surgery are registered stakeholders of the Specialised Cancer Surgery CRG; both organisations have provided comment on the draft service specification.</p>

<p>Which stakeholders have actually been involved?</p>	<p>The draft service specification was sent to the following clinical reference groups and their registered stakeholders for comment:</p> <ul style="list-style-type: none"> <li>• Specialised Cancer Surgery CRG and their registered stakeholders;</li> <li>• Children and Young People’s CRG and their registered stakeholders;</li> <li>• Chemotherapy CRG and their registered stakeholders;</li> <li>• Radiotherapy CRG and their registered stakeholders.</li> </ul> <p>The draft service specification was also sent to all the Clinical Chairs of the existing Sarcoma Advisory Groups (SAGs) for their input.</p> <p>In addition, the draft service specification was sent to the HIV CRG Chair and Lead Commissioner to provide any additional comments on the draft service specification in relation to Kaposi’s sarcoma.</p>
<p>Explain reason if there is any difference from previous question</p>	<p>Not applicable.</p>
<p>Identify any particular stakeholder organisations that may be key to the specification development that you have approached that have yet to be engaged. Indicate why?</p>	<p>None identified.</p>
<p>How have stakeholders been involved? What engagement</p>	<p>So far, stakeholder engagement has taken place in preparation for consultation.</p> <p>On line survey.</p>

<p>methods have been used?</p>	
<p>What has happened or changed as a result of their input?</p>	<p>21 responses were received to stakeholder testing. As result of feedback, the following amendments have been made to the draft service specification:</p> <ul style="list-style-type: none"> <li>• Clarification added into the service specification regarding the diagnosis and management of children and teenagers and young adults (C/TYA) with sarcoma and the links between the sarcoma MDT and the C/TYA PTCs. Amended sections in the service specification have been drafted jointly with the Chair of the Children and Young People’s Cancer CRG;</li> <li>• Further clarification added into the draft service specification regarding the service configuration, the current number of providers and the role of the SAG;</li> <li>• Standards for the minimum caseloads for retro-peritoneal sarcomas and gastro-intestinal sarcomas amended to ensure these read as “should do” standards as opposed to “must to”.</li> <li>• Additional information on the publication of outcomes added into the draft service specification;</li> <li>• Section added in regarding pathology and molecular testing;</li> <li>• Amendments made to the section relating to chest wall and lung sarcomas in line with stakeholder feedback;</li> <li>• Metric on 90 day mortality added into the quality indicators table; and</li> <li>• Designated provider list updated for soft tissue to reflect recent provider mergers.</li> </ul>
<p>How are stakeholders being kept informed of progress with specification development as a result of their input?</p>	<p>Members of the relevant CRGs will be kept informed of the changes, including the relevant Royal Colleges/Associations via the CRGs (both the Royal College of Surgeons and BASO are part of the Specialised Cancer Surgery CRG).</p> <p>All registered stakeholders will be notified when the draft service specification goes out to public consultation.</p>
<p>What level of wider public consultation is recommended by the CRG for the NPOC Board to agree</p>	<p>There was mixed feedback during stakeholder testing regarding the proposed public consultation. The CRG is proposing a 6 week public consultation in line with the majority of feedback received during stakeholder testing.</p>

as a result of stakeholder involvement?	
---	--